Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could Humanigen Stock Soar Even Higher After Its COVID Antibody Results?

TheMotleyFool

0 0

Could Humanigen Stock Soar Even Higher After Its COVID Antibody Results?

Humanigen (NASDAQ: HGEN) recently announced impressive results from a late-stage study of its COVID-19 antibody therapy lenzilumab. The biotech stock skyrocketed on the news but subsequently gave up some of its gains. In this Motley Fool Live video recorded on March 31, Motley Fool contributors Keith Speights and Brian Orelli talk about whether or not Humanigen stock could soar even higher going forward.

Source Fool.com

Like: 0

HGEN

Share